Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
Clinical & Developmental Immunology|March 5, 2008
IPEX as a result of mutations in FOXP3Hans J J van der Vliet, Edward E NieuwenhuisJournal of Immunotherapy (Hagerstown, Md. : 1997)|August 2, 2007
Exploiting regulatory T-cell populations for the immunotherapy of cancerHans J J van der Vliet, Henry B Koon, Michael B Atkins, et al.Journal of Virology|March 23, 2007
Hepatitis C virus (HCV)-specific CD8+ cells produce transforming growth factor beta that can suppress HCV-specific T-cell responsesNadia Alatrakchi, Camilla S Graham, Hans J J van der Vliet, et al.Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2008
Circulating myeloid dendritic cells of advanced cancer patients result in reduced activation and a biased cytokine profile in invariant NKT cellsHans J J van der Vliet, Ruojie Wang, Simon C Yue, et al.Journal of Immunological Methods|March 9, 2007
Generation and sustained expansion of mouse spleen invariant NKT cell lines with preserved cytokine releasing capacityJohan W Molling, Maria Moreno, Hans J J van der Vliet, et al.Clinical Immunology (Orlando, Fla.)|September 12, 2008
Invariant natural killer T cells and immunotherapy of cancerJohan W Molling, María Moreno, Hans J J van der Vliet, et al.Immunology Letters|April 15, 2008
Chronically stimulated mouse invariant NKT cell lines have a preserved capacity to enhance protection against experimental tumor metastasesJohan W Molling, María Moreno, Jan de Groot, et al.Clinical Immunology (Orlando, Fla.)|June 23, 2004
The immunoregulatory role of CD1d-restricted natural killer T cells in diseaseHans J J van der Vliet, Johan W Molling, B Mary E von Blomberg, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 5, 2008
Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapyWeihua Song, Hans J J van der Vliet, Yu-Tzu Tai, et al.Blood|July 2, 2002
MUTZ-3, a human cell line model for the cytokine-induced differentiation of dendritic cells from CD34+ precursorsAllan J Masterson, Claudia C Sombroek, Tanja D De Gruijl, et al.Pageof 2